Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 3/20 | 0.35 |
| ▸ | ACP1 | P24666 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840151 | 0.93 | HTR4 (0.41) | HTR4NPY1RSLC6A4TLR7MERTK | |
| SCHEMBL6833713 | 0.85 | NPY1R (0.39) | HTR4NPY1RSLC6A4TLR7MERTK | |
| SCHEMBL6840049 | 0.83 | ALDH1A1 (0.38) | HTR4NPY1RSLC6A4MERTKKHK | |
| SCHEMBL6838758 | 0.83 | ADORA3 (0.45) | HTR4NPY1RTLR7ACP1ADRB2 | |
| SCHEMBL6833712 | 0.82 | ADORA3 (0.46) | HTR4NPY1RTLR7 | |
| SCHEMBL6840139 | 0.82 | ACP1 (0.38) | HTR4NPY1RTLR7MERTKACP1 | |
| SCHEMBL6833989 | 0.82 | HTR4 (0.37) | HTR4NPY1RSLC6A4TLR7MERTK | |
| SCHEMBL6929019 | 0.82 | NPY1R (0.43) | HTR4NPY1RSLC6A4TLR7ACP1 | |
| SCHEMBL6838577 | 0.82 | PDE6D (0.37) | HTR4NPY1RTLR7MERTKACP1 | |
| SCHEMBL6833751 | 0.82 | ACP1 (0.38) | HTR4NPY1RTLR7MERTKACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | HTR4 2764/4885CNR2 467/4885NPY1R 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.